However, the TARF study also documented that appropriately instituted statin therapy in population subsets prone to MetS or enhanced low-grade inflammation may increase CHD risk in a primary prevention setting.[32] Excess risk imparting may be attributed to a modifying effect of statins on Lp(a). The gene discussed is LPA; the disease is metabolic syndrome.